Colorectal Cancer: Incidence and Time to Recurrence
In a nationwide Danish cohort study reported in JAMA Oncology, Nors et al found the 5-year risk of recurrence after surgery for stage I to III colorectal...
Toxicities Potentially Linked to Combination Immunotherapy for Mesothelioma
The combination of ipilimumab and nivolumab may result in a higher levels of toxicities in patients with unresectable pleural mesothelioma than was reported...
Regular Screening Mammograms May Significantly Reduce Breast Cancer Mortality, Swedish Study Shows
Patients who regularly attend screening mammograms may have a reduced risk of breast cancer mortality, according to recent findings presented by Smith...
Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC
In the phase II SPRINT trial reported in the Journal of Clinical Oncology, Ohri et al found that a chemotherapy-sparing regimen of pembrolizumab with risk-adapted...
Long-Term Organ Preservation With Total Neoadjuvant Therapy in Rectal Adenocarcinoma
In a 5-year follow-up of the phase II OPRA trial reported in the Journal of Clinical Oncology, Verheij et al found that many patients receiving total neoadjuvant therapy...
Richard J. Boxer, MD, FACS: The Future Priorities of the National Cancer Institute
Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma
William J.M. Hrushesky, MD, FACP, ABIM IM & MO: Perspectives on Cancer Therapy Development
Nagi El Saghir, MD, FACP, FASCO: On the Art of Organizing Best of ASCO Meetings
Noelle K. LoConte, MD: ‘I Want to Kill You’
Sponsored Content
Sponsored by Bristol Myers Squibb
First-Line Treatment of PD-L1–Negative Non–Small Cell Lung Cancer
SPONSORED BY LILLY MEDICAL AFFAIRS
Treatment Considerations for Relapsed or Refractory Mantle Cell Lymphoma
HIPEC With Carboplatin for Platinum-Sensitive Recurrent Ovarian Cancer: Safety and Outcomes
In an MSK Team Ovary–led phase II trial reported in the Journal of Clinical Oncology, Zivanovic et al found that use of hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin during secondary cytoreduction followed by chemotherapy did not improve 24-month progression-free survival in...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
KEYNOTE-361: First-Line Pembrolizumab With or Without Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Carcinoma
As reported in The Lancet Oncology by Thomas Powles, MD, PhD, and colleagues, the phase III KEYNOTE-361 trial has shown no significant improvement in progression-free or overall survival with first-line pembrolizumab plus platinum-based chemotherapy vs chemotherapy alone in patients with advanced...
ADAPT: Survival Outcomes After Neoadjuvant Dual HER2 Therapy for HR-Negative, HER2-Positive Breast Cancer
The first overall survival analysis of the WSG-ADAPT HR-/HER2+ study, which evaluated neoadjuvant therapy in patients with hormone receptor (HR)-negative, HER2-positive breast cancer, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or the chemotherapy-free regimen of...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Reduced-Intensity Conditioning Allogeneic HCT Based on Donor Availability in Older Patients With Advanced Myelodysplastic Syndrome
In a study reported in the Journal of Clinical Oncology, Nakamura et al found that use of reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) in older patients with advanced myelodysplastic syndrome (MDS) with an available matched donor improved overall survival vs...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
